Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line

Hye Jung Cho; Mohammed Ibrahim El-Gamal; Chang Hyun Oh; So Ha Lee; Taebo Sim; Garam Kim; Hong Seok Choi; Jung Hoon Choi; Kyung Ho Yoo

doi:10.1248/cpb.c13-00283

Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line

Hye Jung Cho, Mohammed Ibrahim El-Gamal, Chang Hyun Oh, So Ha Lee, Taebo Sim, Garam Kim, Hong Seok Choi, Jung Hoon Choi, Kyung Ho Yoo

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Design and synthesis of a new series of quinolinylaminoisoquinoline derivatives as conformationally restricted bioisosteres of Sorafenib are described. Their in vitro antiproliferative activity against A375P melanoma cell line was tested. Compounds 1b, 1d, 1g, and 1j showed the highest potency against A375P cell line with IC₅₀ values in sub-micromolar scale. In addition, compound 1d exerted high selectivity towards RAF1 serine/threonine kinase with 96.47% inhibition at 10 μM, and IC₅₀ of 0.96 μM. This compound can possess antiproliferative activity against melanoma cells through inhibition of RAF1 kinase.

Original language	English
Pages (from-to)	747-756
Number of pages	10
Journal	Chemical and Pharmaceutical Bulletin
Volume	61
Issue number	7
DOIs	https://doi.org/10.1248/cpb.c13-00283
Publication status	Published - 2013 Jul

Keywords

Antiproliferative activity
Bioisostere
Melanoma
Quinolinylaminoisoquinoline
Sorafenib

ASJC Scopus subject areas

General Chemistry
Drug Discovery

Access to Document

10.1248/cpb.c13-00283

Cite this

Cho, H. J., El-Gamal, M. I., Oh, C. H., Lee, S. H., Sim, T., Kim, G., Choi, H. S., Choi, J. H., & Yoo, K. H. (2013). Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line. Chemical and Pharmaceutical Bulletin, 61(7), 747-756. https://doi.org/10.1248/cpb.c13-00283

Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line. / Cho, Hye Jung; El-Gamal, Mohammed Ibrahim; Oh, Chang Hyun et al.
In: Chemical and Pharmaceutical Bulletin, Vol. 61, No. 7, 07.2013, p. 747-756.

Research output: Contribution to journal › Article › peer-review

Cho, HJ, El-Gamal, MI, Oh, CH, Lee, SH, Sim, T, Kim, G, Choi, HS, Choi, JH & Yoo, KH 2013, 'Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line', Chemical and Pharmaceutical Bulletin, vol. 61, no. 7, pp. 747-756. https://doi.org/10.1248/cpb.c13-00283

@article{97d36d93e20d4e928ff06fff4797cc3c,

title = "Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line",

abstract = "Design and synthesis of a new series of quinolinylaminoisoquinoline derivatives as conformationally restricted bioisosteres of Sorafenib are described. Their in vitro antiproliferative activity against A375P melanoma cell line was tested. Compounds 1b, 1d, 1g, and 1j showed the highest potency against A375P cell line with IC50 values in sub-micromolar scale. In addition, compound 1d exerted high selectivity towards RAF1 serine/threonine kinase with 96.47% inhibition at 10 μM, and IC50 of 0.96 μM. This compound can possess antiproliferative activity against melanoma cells through inhibition of RAF1 kinase.",

keywords = "Antiproliferative activity, Bioisostere, Melanoma, Quinolinylaminoisoquinoline, Sorafenib",

author = "Cho, {Hye Jung} and El-Gamal, {Mohammed Ibrahim} and Oh, {Chang Hyun} and Lee, {So Ha} and Taebo Sim and Garam Kim and Choi, {Hong Seok} and Choi, {Jung Hoon} and Yoo, {Kyung Ho}",

year = "2013",

month = jul,

doi = "10.1248/cpb.c13-00283",

language = "English",

volume = "61",

pages = "747--756",

journal = "Chemical and Pharmaceutical Bulletin",

issn = "0009-2363",

publisher = "Pharmaceutical Society of Japan",

number = "7",

}

TY - JOUR

T1 - Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors

T2 - Design, synthesis, and antiproliferative activity against melanoma cell line

AU - Cho, Hye Jung

AU - El-Gamal, Mohammed Ibrahim

AU - Oh, Chang Hyun

AU - Lee, So Ha

AU - Sim, Taebo

AU - Kim, Garam

AU - Choi, Hong Seok

AU - Choi, Jung Hoon

AU - Yoo, Kyung Ho

PY - 2013/7

Y1 - 2013/7

N2 - Design and synthesis of a new series of quinolinylaminoisoquinoline derivatives as conformationally restricted bioisosteres of Sorafenib are described. Their in vitro antiproliferative activity against A375P melanoma cell line was tested. Compounds 1b, 1d, 1g, and 1j showed the highest potency against A375P cell line with IC50 values in sub-micromolar scale. In addition, compound 1d exerted high selectivity towards RAF1 serine/threonine kinase with 96.47% inhibition at 10 μM, and IC50 of 0.96 μM. This compound can possess antiproliferative activity against melanoma cells through inhibition of RAF1 kinase.

AB - Design and synthesis of a new series of quinolinylaminoisoquinoline derivatives as conformationally restricted bioisosteres of Sorafenib are described. Their in vitro antiproliferative activity against A375P melanoma cell line was tested. Compounds 1b, 1d, 1g, and 1j showed the highest potency against A375P cell line with IC50 values in sub-micromolar scale. In addition, compound 1d exerted high selectivity towards RAF1 serine/threonine kinase with 96.47% inhibition at 10 μM, and IC50 of 0.96 μM. This compound can possess antiproliferative activity against melanoma cells through inhibition of RAF1 kinase.

KW - Antiproliferative activity

KW - Bioisostere

KW - Melanoma

KW - Quinolinylaminoisoquinoline

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84880029086&partnerID=8YFLogxK

U2 - 10.1248/cpb.c13-00283

DO - 10.1248/cpb.c13-00283

M3 - Article

C2 - 23812399

AN - SCOPUS:84880029086

SN - 0009-2363

VL - 61

SP - 747

EP - 756

JO - Chemical and Pharmaceutical Bulletin

JF - Chemical and Pharmaceutical Bulletin

IS - 7

ER -

Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: Design, synthesis, and antiproliferative activity against melanoma cell line

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this